Tempus AI announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company’s PurIST® algorithmic diagnostic. The study provides the largest real-world evidence to date supporting the integration of PurIST into routine clinical care for patients with advanced pancreatic ductal adenocarcinoma (PDAC).
The PurIST® algorithm aims to inform first-line chemotherapy selection for patients with advanced PDAC, a cancer type known for its aggressive nature and limited treatment options. This validation reinforces the diagnostic's ability to provide personalized insights for treatment decisions.
This publication highlights Tempus's commitment to developing and validating AI-driven diagnostic tools that can significantly impact patient outcomes. The evidence supports broader adoption of PurIST® in clinical practice to optimize therapeutic strategies for pancreatic cancer patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.